These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27211481)

  • 1. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.
    Zhang T; Kingwell E; De Jong HJ; Zhu F; Zhao Y; Carruthers R; Petkau J; Gustafson P; Oger J; Tremlett H
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1150-1159. PubMed ID: 27211481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.
    Zhang T; Kingwell E; Zhu F; Petkau J; Kastrukoff LF; Marrie RA; Tremlett H; Evans C
    BMJ Open; 2017 Sep; 7(9):e018612. PubMed ID: 28965103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Harding KE; Wardle M; Carruthers R; Robertson N; Zhu F; Kingwell E; Tremlett H
    Neurology; 2019 Mar; 92(13):e1497-e1506. PubMed ID: 30796140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of secondary progressive multiple sclerosis after early worsening of disability.
    Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
    J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-interferon exposure and onset of secondary progressive multiple sclerosis.
    Zhang T; Shirani A; Zhao Y; Karim ME; Gustafson P; Petkau J; Evans C; Kingwell E; van der Kop M; Zhu F; Oger J; Tremlett H;
    Eur J Neurol; 2015 Jun; 22(6):990-1000. PubMed ID: 25846809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability progression in aggressive multiple sclerosis.
    Menon S; Zhu F; Shirani A; Oger J; Freedman MS; Tremlett H
    Mult Scler; 2017 Mar; 23(3):456-463. PubMed ID: 27325603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
    Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
    Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians.
    Kalnina J; Trapina I; Sjakste N; Paramonova N
    Neurol Sci; 2024 Jul; 45(7):3347-3358. PubMed ID: 38393441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Burman J; Zelano J
    Neurology; 2017 Dec; 89(24):2462-2468. PubMed ID: 29117950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.